Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares traded 11.41% higher at $4.10 on Wall Street last session.
ZNTL stock price is now 15.21% away from the 50-day moving average and -59.63% away from the 200-day moving average. The market capitalization of the company currently stands at $291.55M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $4, Wedbush recently Upgraded its rating from Underperform to Neutral for Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL). On June 20, 2024, UBS Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $28 to quote $5, while ‘Wells Fargo’ rates the stock as ‘Equal Weight’
In other news, Gallagher Cam, President, Interim CFO sold 9,597 shares of the company’s stock on May 31 ’24. The stock was sold for $114,972 at an average price of $11.98. Upon completion of the transaction, the President, Interim CFO now directly owns 633,680 shares in the company, valued at $2.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 09 ’24, Chief Medical Officer HAUSMAN DIANA sold 3,356 shares of the business’s stock. A total of $42,353 was realized by selling the stock at an average price of $12.62. This leaves the insider owning 373,876 shares of the company worth $1.53 million. A total of 13.75% of the company’s stock is owned by insiders.
During the past 12 months, Zentalis Pharmaceuticals Inc has had a low of $2.83 and a high of $23.52. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 6.59, and a quick ratio of 6.59. The fifty day moving average price for ZNTL is $3.5571 and a two-hundred day moving average price translates $10.123575 for the stock.
The latest earnings results from Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was released for 2024-06-30. The net profit margin was -479.92% and return on equity was -42.98% for ZNTL.
